September 2025 The European Vaccine Initiative (EVI) was represented at the IMPRINT Network Conference 2025, held in Johannesburg, South...

Dr. Charles Mulamba, recipient of European Vaccine Initiative PhD fellowship, successfully graduated last week at Nelson Mandela African Institution of Science and Technology, Tanzania.

Working with the Inno4Vac consortium coordinated by European Vaccine Initiative, Naobios will leverage Nuvonis’s Vero Cell Bank to...

This EVI-sponsored clinical trial of the full-length MSP1/GLA-SE vaccine candidate, reflects our commitment to innovation in malaria vaccine development.

New EVI-led project aims to boost malaria control with innovative vaccine technology through international partnership and support by the Global Health Innovative Technology (GHIT) Fund with an investment of approximately JPY 800 million. The core aim of SEmalvac6 is to advance the biomanufacture and preclinical development of the blood-stage malaria vaccine candidate SE36/cVLP.

The SUNSHINE trial has now proceeded to the start of vaccination of participants living in Shigella endemic setting at the Centre for Infectious Disease Research in Zambia (CIDRZ).

A delegation from BioNTech visited the European Vaccine Initiative (EVI) to engage in a dialogue focused on strengthening global capacity building efforts and supporting scientific training for fellows hosted by both organisations. 

An interactive online workshop titled “Strategies for using Malaria vaccines to prevent Malaria in pregnancy” was held on June 3rd,...

The courses were led by the EVI and designed to strengthen capacity in vaccine research and development (R&D), with a particular focus on supporting professionals from low- and middle-income countries (LMICs).

World Malaria Day is observed every year on 25 April to recognise global efforts to control malaria.

The OPT-MVAC consortium will support the rollout of malaria vaccines in 14 Central and West African countries.

An inactivated Hepatitis C vaccine showing promising results in preclinical trials moves closer to human trials, with a new project to establish and optimise production and manufacture of the vaccine.

New EVI-led project will assess the impact of enhancing seasonal malaria vaccination in Guinea and Benin. The findings could shape future...

EVI launched Phase II clinical trial to evaluate the R21/Matrix-M malaria vaccine (by Univ. of Oxford), in women of childbearing potential.

March 24 marks World Tuberculosis Day on the anniversary of Dr. Robert Koch's groundbreaking discovery of Mycobacterium tuberculosis in 1882

From establishing a strong clinical trial network to accelerating vaccine research and fostering cross-border collaboration, VACCELERATE...

A newly published article outlines the protocol for new phase Ia/b clinical trial for the Invaplex AR-Detox  Shigella vaccine...

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the TRANSVAC project, funded by the EC.

Phase 1 clinical trials in the UK and Burkina Faso showed that the malaria vaccine candidate, R21 adjuvanted with Matrix-M, has an...

Neglected Tropical Diseases (NTDs) cause immense suffering and affect an estimated 1 billion people mostly in isolated and marginalised...

At the World Vaccine Congress 2024, an EVI-organised panel discussion explored the lessons learnt from licensed malaria vaccines.

Understanding cultural beliefs and practices around pregnancy and vaccination Our ethnographic study in Malawi—focused on understanding...

November 2024 Last week, the EVI team gathered in Frankfurt for a retreat designed to recharge, step away from our daily routines, and...

T he European Vaccine Initiative (EVI) proudly participated in the Product Development Partnerships (PDP) IV Annual Meeting on November...